Skip to Content

Cerevel Therapeutics Holdings, Inc.

Securities Class Action

  • Date:
  • 6/3/2025
  • Company Name:
  • Cerevel Therapeutics Holdings, Inc.
  • Stock Symbol:
  • CERE
  • Class Period:
  • FROM 10/11/2023 TO 8/1/2024
  • Status:
  • Filed
  • Filing Date:
  • 4/3/2025
  • Court:
  • U.S. District Court: District of Delaware

Case Finder

Locate any case using the tools below.

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Cerevel Therapeutics Holdings, Inc. (“Cerevel” or the “Company”) (CERE) in the United States District Court for the District of Delaware on behalf of all persons and entities who purchased or otherwise acquired Cerevel securities from October 11, 2023 through August 1, 2024, both dates inclusive (the “Class Period”). Investors have until June 3, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

The Complaint alleges that Cerevel's Offering documents and other public statements omitted material facts regarding AbbVie's interest in acquiring Cerevel at a price well in excess of the $22.81 per share Offering price, artificially deflating Cerevel's stock price until the merger was announced. Moreover, Specifically, the Complaint alleges that: (1) Cerevel's controlling shareholder, Bain, acquired Cerevel shares from the October Offering at an artificially depressed price while allegedly in possession of material nonpublic information regarding AbbVie's interest; (2) On December 6, 2023 (less than two months after the October Offering), Cerevel publicly announced that AbbVie agreed to acquire Cerevel for $45 per share and that the merger allowed Bain to receive a windfall of more than $120 million on the shares it acquired at the artificially depressed Offering price.
 
The Action also seeks to recover damages on behalf of investors that held shares as of the January 8, 2024 Record Date and were damaged as a result of Defendants' allegedly false and misleading statements and omissions of material facts in Cerevel's January 18, 2024 Proxy statement (the "Proxy"). Among other things, the Complaint alleges the Proxy misled investors regarding the true nature and timing of AbbVie's interest in Cerevel.
 
If you purchased or otherwise acquired Cerevel shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out the form below.  There is no cost or obligation to you.
Contact Instructions
Please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com with any questions about this case.
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Cerevel Therapeutics Holdings. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: